Skip to main content

Advertisement

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Correction to: BMC Cancer (2018) 18:1198

DOI: 10.1186/s12885-018-5110-2

Following publication of the original article [1], the authors notified us of a typographical error in Table 1.

Table 1 Patient Baseline Characteristics. The baseline demographics and clinical characteristics of patients with advanced EGFRm + NSCLC treated with first-line afatinib (n = 125) in our cohort

The corrected Table 1 is presented below.

Reference

  1. 1.

    Tan, et al. Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. 2018, 2018;18:1198. https://doi.org/10.1186/s12885-018-5110-2.

Download references

Author information

Correspondence to Darren Wan-Teck Lim.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tan, W., Ng, Q.S., Lim, C. et al. Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. BMC Cancer 18, 1288 (2018). https://doi.org/10.1186/s12885-018-5215-7

Download citation